“Our life sciences and capital markets practices continue to see significant client activity and demand for ongoing securities compliance and financing transactions,” said Mitchell Bloom, chair of Goodwin’s Life Sciences practice. “As we anticipate this momentum to continue, Marianne’s impressive experience in both domestic and foreign transactions will be a great complement to our market-leading practice.”
Sarrazin represents clients on a wide variety of capital markets transactions, including traditional IPOs or alternative paths to public (reverse mergers or deSPAC transactions), along with follow-on offerings, at-the-market offerings and PIPEs. She also frequently serves as outside general counsel to her public company clients, closely advising management teams and boards of directors on a wide variety of matters, including ongoing SEC reporting and U.S. securities law requirements, as well as Nasdaq/NYSE compliance and other corporate governance matters.
U.S. News — Best Lawyers’ 2021 edition named Goodwin the Biotechnology Law Firm of the Year for the sixth time. LMG Life Sciences also named Goodwin firm of the year for 2020 in the corporate, lifecycle, and intellectual property categories. Mergermarket’s Deal Drivers FY20 reports named Goodwin the number one firm (by deal count) for Pharma, Medical, and Biotech M&A in North America and the number two firm (by value) for Pharma, Medical, and Biotech M&A in Europe, the Middle East, and Africa.
Goodwin’s Life Sciences practice represents leading public and private life sciences companies and investors across their entire life cycles — including financings, capital market transactions, M&A, collaborations and licensing, intellectual property, and regulatory matters.